SCHEMBL899630

SCHEMBL899630

COc1ccc(NC(=O)OC(C)(C)C)cc1-c1noc(C)c1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.47
GHSR Q92847 1/20 0.45
ALDH1A1 P00352 4/20 0.43
GAA P10253 2/20 0.43
TSHR P16473 6/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
AGPAT2 O15120 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 1/20 0.40
CRHBP P24387 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12691878 0.88 CA12 (0.45) ALDH1A1GAATSHRHTTKDM4E
SCHEMBL899024 0.88 GHSR (0.46) PTGS2GHSRALDH1A1GAATSHR
SCHEMBL12691800 0.76 MAPT (0.43) ALDH1A1GAAHTTKDM4EL3MBTL1
SCHEMBL899594 0.76 TSHR (0.47) PTGS2GHSRALDH1A1TSHRHTT
SCHEMBL457431 0.73 GPBAR1 (0.62) GHSRALDH1A1GAATSHRKDM4E
SCHEMBL986492 0.73 ALDH1A1 (0.55) ALDH1A1GAAKDM4ECA12CA1
SCHEMBL18467344 0.73 ALDH1A1 (0.58) ALDH1A1GAAKDM4ECA12CA1
SCHEMBL899646 0.73 MEN1 (0.49) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL10809983 0.73 ALDH1A1 (0.72) ALDH1A1GAAKDM4EL3MBTL1NPSR1
SCHEMBL17652660 0.71 ALDH1A1 (0.49) ALDH1A1GAAKDM4ECA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621920-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS Bristol-Myers Squibb Company (US) 2013-08-07 EP disclosed
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-27 US disclosed
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-27 US disclosed
WO-2012044531-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS ZC3HAV1, ZC3HAV1L, BAZ2A PTGS2 1845/4885GHSR 1417/4885ALDH1A1 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.